Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma
| Autor: | V. Georgoulias, A. Argyraki, A. Geroyianni, C.-H. Christophylakis, N. Karvounis, S. Kakolyris, A. Agelidou, Charalambos Kouroussis, E. Tsaroucha, M. Agelidou, M. Veslemes, Nikos Androulakis |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Cancer Research medicine.medical_specialty Lung Neoplasms Maximum Tolerated Dose Paclitaxel EP Regimen medicine.medical_treatment Population Urology Antineoplastic Combined Chemotherapy Protocols medicine Humans Carcinoma Small Cell Lung cancer education Lung Survival rate Etoposide Aged Neoplasm Staging education.field_of_study Chemotherapy business.industry Middle Aged medicine.disease Combined Modality Therapy Surgery Survival Rate Regimen Treatment Outcome Oncology Female Cisplatin business Febrile neutropenia medicine.drug |
| Zdroj: | Lung Cancer. 53:59-65 |
| ISSN: | 0169-5002 |
| Popis: | Summary Purpose To evaluate the efficacy and tolerance of a cisplatin plus etoposide regimen followed by thoracic radiotherapy (TRT) and paclitaxel plus cisplatin consolidation chemotherapy in patients with limited stage small cell lung cancer (SCLC). Patients and methods Thirty-nine patients with limited SCLC were enrolled onto this study. Patients received three courses of cisplatin 75 mg/m2 IV, day 1 and etoposide 100 mg/m2 IV, days 1–3 (EP regimen), followed by TRT (45–56 Gy administered in 15 fractions), and three courses of paclitaxel 175 mg/m2 IV, day 1 and cisplatin, as previously, on day 2 (PP regimen); cycles were repeated every 21 days. Results All patients were evaluable for toxicity and 34 for response. The overall response rate was 67% (CR: 26%; PR: 41%; intention-to-treat analysis) (95% CI: 53.0–84.2%). After a median follow-up period of 15 months, the median survival time was 15 months, the median time to tumor progression 8.3 months and the 1-year survival rate 53.8%. Grade 3/4 neutropenia occurred in 39% and 36% of patients receiving EP and PP regimens, respectively. The incidence of febrile neutropenia was 5% and 3% for EP and PP regimens, respectively. Other hematologic and non-hematologic toxicities were mild, with the exception of esophagitis occuring in 36% of patients during and/or immediately after radiotherapy. Conclusion Consolidation therapy with PP after sequential EP and thoracic radiotherapy is feasible and well-tolerated; however, the efficacy results are comparable with those previously obtained in the same patients’ population using a combination of EP and TRT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect